TABLE 8

Comparison of SVR12 rates in the presence and absence of baseline polymorphisms in NS3 or NS5A in GT3-infected patients

Patient group and BPaSVR12 rate (%) by prior treatment experience, treatment duration, and BP statusb
TN (8 wk)TN (12 wk)TE-PRS (12 wk)TE-PRS (16 wk)
With BPWithout BPWith BPWithout BPWith BPWithout BPWith BPWithout BP
No cirrhosis
    NS3
        T54(A/S)50 (1/2)97 (174/179)100 (1/1)99 (250/253)
        A166S82 (14/17)*98 (161/164)*100 (20/20)99 (231/234)80.0 (4/5)90.9 (40/44)100 (2/2)95 (18/19)
        A166T100 (8/8)97 (167/173)100 (13/13)99 (238/241)100 (3/3)89 (41/46)
        Q168K100 (1/1)97 (174/180)100 (3/3)99 (248/251)
        Q168R(0/1)97 (175/180)50 (1/2)*99 (250/252)*
    NS5A
        A30(L/M/S/T/V)100 (13/13)96 (163/169)93 (13/14)c99 (240/242)100 (1/1)90 (43/48)100 (1/1)95 (19/20)
        A30K78 (14/18)***99 (161/163)***93 (13/14)c99 (240/242)25 (1/4)**96 (43/45)**(0/1)100 (20/20)
        V31Mc100 (2/2)97 (173/179)(0/1)*99 (253/255)*100 (1/1)90 (43/48)100 (1/1)95 (19/20)
        Y93H100 (10/10)96 (165/171)91 (10/11)c99 (243/245)50 (2/4)*93 (42/45)*
Compensated cirrhosis
    NS3
        A166S100 (6/6)100 (53/53)60 (3/5)*98 (42/43)*
        A166T100 (3/3)100 (56/56)100 (3/3)93 (42/45)
        Q168K100 (2/2)100 (57/57)
        Q168R100 (1/1)94 (44/47)
    NS5A
        A30(M/R/S/T/V)100 (4/4)100 (55/55)100 (4/4)93 (41/44)
        A30K100 (1/1)100 (58/58)
        V31Md100 (1/1)94 (44/47)
        Y93H100 (5/5)100 (54/54)
  • a Polymorphisms relative to subtype-specific reference sequences at a 15% detection threshold at amino acid positions 36, 43, 54, 55, 56, 80, 155, 156, 166, and 168 in NS3 or 24, 28, 30, 31, 32, 58, 92, and 93 in NS5A were included in the analysis. Only positions where baseline polymorphisms were detected in patients experiencing virologic failure are listed. All GT3 subtypes are included in the analysis. BP, baseline polymorphism.

  • b Values in parentheses are the number of patients with the polymorphism/total number of patients in the group with available sequence. TN, treatment-naive; TE-PRS, treatment-experienced to peg-IFN plus RBV with or without sofosbuvir. *, P = 0.05; **, P = 0.01; ***, P = 0.001 (by Fisher's exact test).

  • c The patient experiencing virologic failure had A30K, A30V, and Y93H at baseline.

  • d NS5A-V31M was detected only in GT3b-infected patients.